Next Article in Journal
Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases
Next Article in Special Issue
Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation
Previous Article in Journal
Implication of Heat Shock Factors in Tumorigenesis: Therapeutical Potential
Previous Article in Special Issue
Muscarinic Receptor Signaling in Colon Cancer
Article Menu

Export Article

Open AccessReview
Cancers 2011, 3(1), 1182-1194; doi:10.3390/cancers3011182

Cardiac Hormones Target the Ras-MEK 1/2-ERK 1/2 Kinase Cancer Signaling Pathways

Departments of Internal Medicine, Molecular Pharmacology and Physiology, Cardiac Hormone Center, University of South Florida Health Sciences Center, J. A. Haley Veterans Medical Center-151, 13000 Bruce B. Downs Blvd., Tampa, Florida 33612, USA
Received: 18 February 2011 / Revised: 2 March 2011 / Accepted: 3 March 2011 / Published: 8 March 2011
(This article belongs to the Special Issue Cancer Signaling Pathways and Crosstalk)
View Full-Text   |   Download PDF [340 KB, 9 March 2011; original version 8 March 2011]   |  

Abstract

The heart is a sophisticated endocrine gland synthesizing the atrial natriuretic peptide prohormone which contains four peptide hormones, i.e., atrial natriuretic peptide, vessel dilator, kaliuretic peptide and long-acting natriuretic peptide, which decrease up to 97% of human pancreatic, breast, colon, prostate, kidney and ovarian carcinomas as well as small-cell and squamous cell lung cancer cells in cell culture. In vivo, these four cardiac hormones eliminate up to 80% of human pancreatic adenocarcinomas, two-thirds of human breast cancers, and up to 86% of human small-cell lung cancers growing in athymic mice. Their signaling in cancer cells includes inhibition of up to 95% of the basal activity of Ras, 98% inhibition of the phosphorylation of the MEK 1/2 kinases and 97% inhibition of the activation of basal activity of the ERK 1/2 kinases mediated via the intracellular messenger cyclic GMP. They also completely block the activity of mitogens such as epidermal growth factor’s ability to stimulate ERK and Ras. They do not inhibit the activity of ERK in healthy cells such as human fibroblasts. The final step in their anticancer mechanism of action is that they enter the nucleus as demonstrated by immunocytochemical studies to inhibit DNA synthesis within cancer cells. View Full-Text
Keywords: Ras; MEK 1/2 kinases; ERK 1/2 kinases; DNA synthesis; cancer; signaling Ras; MEK 1/2 kinases; ERK 1/2 kinases; DNA synthesis; cancer; signaling
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Vesely, D.L. Cardiac Hormones Target the Ras-MEK 1/2-ERK 1/2 Kinase Cancer Signaling Pathways. Cancers 2011, 3, 1182-1194.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top